Exposure to Certain HIV Drugs May Significantly Lower Risk for Alzheimer Disease
By Elana Gotkine HealthDay Reporter
TUESDAY, May 20, 2025 -- Exposure to nucleoside reverse transcriptase inhibitors (NRTIs), which treat HIV and hepatitis B and inhibit inflammasome activation, is associated with a significantly lower incidence of Alzheimer disease (AD), according to a study published online May 8 in Alzheimer's & Dementia.
Joseph Magagnoli, from the Dorn Research Institute at the Columbia VA Health Care System in South Carolina, and colleagues examined the association between NRTI exposure and subsequent development of AD during a 24-year period in the U.S. Veterans Health Administration database and during a 14-year period in the MarketScan database.
The researchers found that the incidence of AD was significantly lower in association with NRTI exposure in both health insurance claims databases. In contrast, there was no association seen for exposure to non-NRTIs, protease inhibitors, or integrase strand transfer inhibitors with reduced AD incidence.
"Innate immune signaling through the NLRP3 inflammasome has been implicated in the pathogenesis of AD. A therapy that inhibits inflammasome activation could thus be neuroprotective and improve clinical outcomes in AD," the authors write. "In the present study, we demonstrate that exposure to inflammasome-inhibiting NRTIs is associated with a significantly lower incidence of AD in two of the largest health insurance databases in the United States."
One author disclosed ties to the biopharmaceutical industry; two authors are named as inventors on matter-related patent applications.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2025
Read this next
Cognitive Functional Therapy Effective for Chronic Low Back Pain at Three Years
WEDNESDAY, Aug. 6, 2025 -- Cognitive functional therapy (CFT), with or without biofeedback, is more effective than usual care for treating patients with chronic disabling low back...
Avoidable All-Cause Hospitalization, ED Visits Common in Nursing Homes
MONDAY, Aug. 4, 2025 -- Among severely impaired and terminally ill nursing home (NH) residents, all-cause hospitalizations (ACH) and emergency department visits without...
Average Time to Diagnosis Is 3.5 Years Across All Types of Dementia
FRIDAY, Aug. 1, 2025 -- The mean time to diagnosis (TTD) for dementia is 3.5 years across all types of dementia, according to a review published online July 27 in the...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.